Drugs News and Research

RSS

Combination of LIVALO and itraconazole drugs shows no adverse reactions

...

2 Sep 2009

Ferguson OTC Center of Excellence launched to address increase use of OTC drugs

Ferguson, the founding professional agency of CommonHealth, today announced the launch of the Ferguson OTC (over-the-counter) Center of Excellence, a new initiative designed to address the rapid increase of promotion and use of OTC drugs.

2 Sep 2009

Hope for limiting skin toxicity of cancer drug users

There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.

2 Sep 2009

Neuromuscular disorders common among Canadians

September is Muscular Dystrophy Awareness Month. There are more than 100 neuromuscular disorders and it is estimated more than 50,000 Canadians are affected by one form or another. Each form is caused by an error in a specific gene related to muscle function.

2 Sep 2009

Pre-hospitalization strategies will bring down mortality rate of patients with heart disorders

Mortality rate following a heart attack has fallen by more than 50% in Europe over the past 25 years. However, because only minor advances in the medical treatment of AMI are expected over the next decade, it is through organisational changes in the pre-hospital phase that mortality rate will continue this decline to below 5%.

2 Sep 2009

Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon

A groundbreaking new treatment for obesity is to begin clinical trials in January. Madrona Ventures Inc., an American publicly listed company (OTCBB:MDRV), has acquired the treatment's European patent and the pending American patent application.

2 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp

Knopp Neurosciences Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of KNS-760704 in amyotrophic lateral sclerosis (ALS).

2 Sep 2009

Researchers discover why smoking increases the risk of heart disease and stroke

Researchers have discovered a reason why smoking greatly increases the risk of heart disease and stroke. Nicotine promotes insulin resistance, also called prediabetes, which is a risk factor for cardiovascular disease, according to the new study, which was presented at The Endocrine Society's 91st Annual Meeting in Washington, D.C.

2 Sep 2009

New therapy delays the progression of heart failure

A therapy called cardiac resynchronization can significantly delay the progression of heart failure, according to a major international study published in the New England Journal of Medicine.

2 Sep 2009

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy.

2 Sep 2009

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

In a major international trial, researchers from McMaster University in Canada, found that the hypertension drug irbesartan reduced the risk of heart failure complications and the combination of stroke, other embolic events and transient ischemic events, also known as ministrokes, in patients with atrial fibrillation.

2 Sep 2009

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance. A "death receptor" can possibly provide information as to how great the chances of success are for chemotherapy. At the same time, it offers a new approach for promising brain tumor therapy.

2 Sep 2009

White paper stresses the need for healthy living and prevention to be included in healthcare reform

Healthy living and pharmacy Expert and Commentator Marc Isaacson, CEO of Village Green Apothecary, the leading integrative pharmacy in the United States, announced today the release of their white paper, which provides a statistical analysis that explains why healthy living and prevention should be included, if not the focus of Healthcare Reform.

2 Sep 2009

Scientists shed light on the relationship between hypertension and obesity

Some of the first information about how fat causes hypertension have been identified by researchers who say the findings should one day help identify which obese people - and maybe some thin ones too - are at risk for hypertension and which drugs would work best for them.

2 Sep 2009

Higher education levels associated with an earlier need for symptomatic treatment of Parkinson's disease

Individuals who have higher levels of education and who are more impaired by Parkinson's disease appear to require treatment for their symptoms earlier than do other patients, according to a report posted online today that will appear in the September print issue of Archives of Neurology, one of the JAMA/Archives journals.

2 Sep 2009

New research on post-traumatic stress disorder to be presented at MHRF

New research on post-traumatic stress disorder (PTSD) is being presented this week at the Military Health Research Forum (MHRF), a scientific conference hosted by the Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP). Depending on the conflict in which they served, 10 to 30 percent of soldiers who have spent time in war zones experience the debilitating and life-altering symptoms of post-traumatic stress disorder (PTSD).

2 Sep 2009

Researchers analyze the role of bioactive lipids in inflammatory diseases

According to the National Center for Chronic Disease Prevention and Health Promotion, 46 million Americans have arthritis. Many of these people take over-the-counter anti-inflammatory medications that block production of certain molecules, known as bioactive lipids, to reduce pain and swelling. Yet, the role of these lipids is not yet understood completely, and medications may have adverse side effects.

2 Sep 2009

Legal immigrants to receive scaled back health care benefits in Massachusetts

Thousands of legal immigrants in Massachusetts will face scaled-back health care benefits, the governor announced Monday.

2 Sep 2009

Eye disease medication lowers death rate among Ethiopian children

Children in Ethiopia who received the antibiotic azithromycin as a method for controlling the contagious eye disease trachoma had a lower odds of death compared to children who did not receive the antibiotic, according to a study in the September 2 issue of JAMA.

2 Sep 2009

Drugs News and Research

Combination of LIVALO and itraconazole drugs shows no adverse reactions

Ferguson OTC Center of Excellence launched to address increase use of OTC drugs

Hope for limiting skin toxicity of cancer drug users

Neuromuscular disorders common among Canadians

Pre-hospitalization strategies will bring down mortality rate of patients with heart disorders

Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Knopp Neurosciences to accelerate the development of KNS-760704 in ALS, says CEO of Knopp

Researchers discover why smoking increases the risk of heart disease and stroke

New therapy delays the progression of heart failure

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

White paper stresses the need for healthy living and prevention to be included in healthcare reform

Scientists shed light on the relationship between hypertension and obesity

Higher education levels associated with an earlier need for symptomatic treatment of Parkinson's disease

New research on post-traumatic stress disorder to be presented at MHRF

Researchers analyze the role of bioactive lipids in inflammatory diseases

Legal immigrants to receive scaled back health care benefits in Massachusetts

Eye disease medication lowers death rate among Ethiopian children

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News